{
    "nct_id": "NCT06106633",
    "official_title": "Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization Via Pressure-Enabled Drug Delivery With the TriNav Infusion System (PEDD-UFE)",
    "inclusion_criteria": "1. Female, aged >18 years.\n2. Prior clinical decision for treatment by UFE.\n3. One or more enhancing intramural, submucosal or subserosal fibroids on MRI.\n4. Having either bulk symptoms or menorrhagia.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
    "exclusion_criteria": "1. Absolute contraindication to contrast-enhanced MRI.\n2. Current pregnancy.\n3. Known history of adenomyosis.\n4. Diagnosis of pelvic inflammatory disease.\n5. Diagnosis of endometriosis.\n6. Post-menopausal (no menses >12-months).\n7. Diagnosed gynecologic malignancy.\n8. Prior uterine fibroid embolization treatment.\n9. >50% volume of non-enhancing fibroids.\n10. Prior oophorectomy\n11. GnRH agonist therapy within 6-months or GnRH antagonist therapy within 1-month prior to entering the study.\n12. Target uterine vasculature not suitable for treatment with the TriNav Infusion System.\n13. Allergy or intolerance to dilaudid.\n14. Lack of ovarian perfusion on baseline MRI.",
    "miscellaneous_criteria": ""
}